3 Stocks Insiders Are Buying: Oracle, Consumer Portfolio Services And More

Although Dow Jones dipped more than 700 points this morning, there were a few notable insider buys.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

Oracle

• The Trade: Oracle Corporation ORCL Director Charles Moorman IV acquired a total of 15000 shares at an average price of $83.76. To acquire these shares, it cost around $1.26 million.
• What’s Happening: Deutsche Bank, on Friday, maintained Oracle with a Buy and lowered the price target from $120 to $110.
• What Oracle Does: Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world.

Consumer Portfolio Services

• The Trade: Consumer Portfolio Services, Inc. CPSS 10% owner Stephen Deckoff acquired a total of 36246 shares at an average price of $10.63. To acquire these shares, it cost $385.29 thousand.
• What’s Happening: The company’s stock jumped 106% over the past six months.
• What Consumer Portfolio Services Does: Consumer Portfolio Services Inc is a US-based company operates in a specialty finance sector. Its business is to purchase and service retail automobile contracts originated primarily by franchised automobile dealers and, to a lesser extent, by select independent dealers in the U.S. in the sale of new and used automobiles, light trucks and passenger vans.

Graphite Bio

• The Trade: Graphite Bio, Inc. GRPH 10% owner Srinivas Akkaraju bought a total of 97670 shares at an average price of $9.10. To acquire these shares, it cost $888.68 thousand.
• What’s Happening: Graphite Bio, last month, presented trial-in-progress poster of Phase 1/2 CEDAR trial evaluating investigational gene editing therapy GPH101 in sickle cell disease at ASH 2021.
• What Graphite Bio Does: Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases.